← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Imcare Biotech, Inc.
Doylestown, PA
$6,763,808
Total funding
4
Grants
Funding over time
peak $1.6M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,763,808 · 4
By mechanism
R44$5,939,857 · 1
R43$657,222 · 2
SB1$166,729 · 1
Investigators at Imcare Biotech, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A novel diagnostic Kit for Hepatocellular Carcinoma$1,420,847
R44 · FY2021 · CA
A novel diagnostic Kit for Hepatocellular Carcinoma$1,289,036
R44 · FY2023 · CA
A novel diagnostic Kit for Hepatocellular Carcinoma$1,283,792
R44 · FY2022 · CA
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$657,468
R44 · FY2016 · CA
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$654,671
R44 · FY2017 · CA
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$632,643
R44 · FY2015 · CA
A novel multi-analyte algorithmic assay diagnostic for hepatocellular carcinoma (HCC).$364,763
R43 · FY2025 · CA
A novel diagnostic biomarker for hepatocellular carcinoma and cholangiocarcinoma$292,459
R43 · FY2012 · CA
Comprehensive Intellectual Property, Reimbursement, and Licensing Strategy for ImCare Biotech's Diagnostic Product Seravue$166,729
SB1 · FY2021 · CA
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$1,400
R44 · FY2018 · CA